Commonwealth Coat of Arms of Australia

 

PB 96 of 2024

 

National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024
(No. 9)

 

National Health Act 1953

 

I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.

Dated 27 September 2024

NIKOLAI TSYGANOV

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

 

 

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015
(PB 120 of 2015). 2

 

1 Name

  1.            This instrument is the National Health (Pharmaceutical benefits – early supply) Amendment Instrument 2024 (No. 9).
  2.            This instrument may also be cited as PB 96 of 2024.

2 Commencement

  1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

1 October 2024

1 October 2024

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

  1.            Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 84AAA(2) of the National Health Act 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical benefits—early supply) Instrument 2015 (PB 120 of 2015)

  1.            Schedule 1, after entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [Maximum quantity or number of units: 2; Maximum number of repeats: 5]

insert:

 

 

20

2

6

 

  1.            Schedule 1, entry for Bimekizumab

substitute:

Bimekizumab

Injection 160 mg in 1 mL single use pre‑filled pen

20

2

1

 

 

 

20

2

2

 

 

 

20

2

4

 

  1.            Schedule 1, entry for Estradiol
  1.            omit:

 

Transdermal patches 2 mg, 4

20

1

5

 

  1.            omit:

 

Transdermal patches 3.8 mg, 4

20

1

5

 

 

Transdermal patches 5.7 mg, 4

20

1

5

 

 

Transdermal patches 7.6 mg, 4

20

1

5

 

  1.            Schedule 1, after entry for Etonogestrel

insert:

Etrasimod

Tablet 2 mg

20

28

3

 

 

 

20

28

5

 

  1.            Schedule 1, entry for Ibrutinib

substitute:

Ibrutinib

Capsule 140 mg

20

90

2

 

 

 

20

90

4

 

 

 

20

90

5

 

 

 

20

120

5

 

 

Tablet 280 mg

20

30

2

 

 

 

20

30

4

 

 

 

20

30

5

 

 

Tablet 420 mg

20

30

2

 

 

 

20

30

4

 

 

 

20

30

5

 

 

Tablet 560 mg

20

30

5

 

  1.            Schedule 1, after entry for Ibrutinib in the form Tablet 560 mg

insert:

Icosapent ethyl

Capsule 998 mg

20

120

5

 

  1.            Schedule 1, after entry for Siponimod in the form Tablet 250 micrograms (as hemifumarate)

insert:

 

Tablet 1 mg (as hemifumarate)

20

28

5

 

  1.            Schedule 1, entry for Tenofovir with emtricitabine

omit:

 

Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg

20

30

2